Collaborations, Clinical Development Programs, FDA Approvals, New Treatments and Attractive Product Portfolios - Research Report on Medivation, Acadia, Santarus, Seattle Genetics, and PDL BioPharma

Mon Jun 10, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

Collaborations, Clinical Development Programs, FDA Approvals, New Treatments and Attractive Product Portfolios - Research Report on Medivation, Acadia, Santarus, Seattle Genetics, and PDL BioPharma

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, June 10, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Medivation, Inc. (NASDAQ: MDVN), ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD), Santarus, Inc. (NASDAQ: SNTS), Seattle Genetics Inc (NASDAQ: SGEN), and PDL BioPharma, Inc. (NASDAQ: PDLI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Medivation, Inc. Research Report

On June 3, 2013, Medivation, Inc., together with Astellas Pharma Inc., announced that after a priority review, Health Canada has approved XTANDI (enzalutamide) capsules for the treatment of patients with metastatic castration-resistant prostate cancer in the setting of medical or surgical castration who have received docetaxel therapy. XTANDI was approved by the US Food and Drug Administration on August 31, 2012. On April 26, 2013, the Companies received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, recommending European Commission approval for XTANDI. An application for marketing approval was submitted to the Ministry of Health, Labour and Welfare in Japan for the treatment of prostate cancer on May 24, 2013. The Full Research Report on Medivation, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [http://www.wsreports.com/r/full_research_report/4e75_MDVN]

--

ACADIA Pharmaceuticals, Inc. Research Report

On June 3, 2013, Acadia Pharmaceuticals, Inc. (Acadia) announced that Allergan, Inc. (Allergan) has advanced an additional product candidate as a potential new treatment for glaucoma. The novel small molecule resulted from joint research conducted by the Companies under their recently concluded research collaboration focused on new therapies for glaucoma and related ophthalmic conditions. "We are delighted that Allergan has advanced another new chemical entity emerging from our collaborative research into preclinical development," said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. "This molecule has demonstrated an attractive profile and has distinctly different properties from other glaucoma compounds advanced under the collaboration. This program benefits greatly from Allergan's expertise and leadership in the eye care field and further illustrates the combined strength of our joint discovery capabilities." The Full Research Report on ACADIA Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [http://www.wsreports.com/r/full_research_report/34b6_ACAD]

--

Santarus, Inc. Research Report

On May 6, 2013, Santarus, Inc. (Santarus) reported its Q1 2013 financial results with total revenues of $79.4 million, up 73% YoY. The Company's net income increased to $18.7 million or diluted EPS of $0.25, from net income of $0.6 million or diluted EPS of $0.01 in Q1 2012. "We are pleased with the strong financial performance in first quarter of 2013 and the substantial increase in revenue and profitability over the prior year period," said Gerald T. Proehl, President and Chief Executive Officer of Santarus. "Based on the strength of our first quarter results we are raising our top and bottom-line financial outlook for 2013." The Company now anticipates its full-year 2013 revenues to be in the range of $330 million to $340 million, up from its previously estimated range of $320 million to $325 million. The Full Research Report on Santarus, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [http://www.wsreports.com/r/full_research_report/28f6_SNTS]

--

Seattle Genetics Inc. Research Report

On June 2, 2013, Seattle Genetics Inc. (Seattle Genetics) highlighted its ongoing clinical development programs for ADCETRIS in frontline Hodgkin lymphoma (HL) and mature T-cell lymphoma (MTCL) and progress with collaborator antibody-drug conjugate (ADC) programs "ADCs represent an innovative and growing field in the fight against cancer, which is evident by the interest in this therapeutic approach at the ASCO annual meeting," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "As the first ADC to be approved by the FDA in this new class, we are focused on broadening the evaluation of ADCETRIS in earlier lines of therapy with our ongoing ECHELON-1 and ECHELON-2 global phase 3 trials, which are designed to redefine the standard of care for frontline treatment of HL and MTCL. While we advance our internal programs, our collaborators are making important progress utilizing our ADC technology. Notably, Genentech is presenting encouraging phase 1 data for two ADC candidates in solid tumor settings." The Full Research Report on Seattle Genetics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [http://www.wsreports.com/r/full_research_report/f796_SGEN]

--

PDL BioPharma, Inc. Research Report

On May 9, 2013, PDL BioPharma, Inc. (PDL BioPharma) reported its Q1 2013 financial results with royalty revenues growth of 19% YoY. The Company's total revenues were $91.8 million, compared to $77.3 million in Q1 2012. The growth in royalty revenues was driven primarily by increased royalties from Q4 2012 sales of Avastin, Herceptin, Lucentis, Tysabri, and Actemra. The Company's net income of $53.5 million or $0.36 per diluted share was higher as compared to $40.2 million or $0.29 per diluted share in the Q1 2012. The Company reported that the increase in net income was driven by the 19% YoY increase in royalty revenues. The Full Research Report on PDL BioPharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [http://www.wsreports.com/r/full_research_report/0666_PDLI]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquires, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


SOURCE Wall Street Reports

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.